Anyone who has followed the biopharma sector over the past decade knows that big pharma's lust for monoclonal antibody technology isn't going away any time soon. But a recent report and webinar by Deloitte Recap LLC, which broke down more than 1,000 deals over the last 10 years, showed some unexpected trends for companies working in the antibody space. Read More
Privately held biotech Signum Biosciences Inc. signaled its intention to play in a bigger sandbox on Wednesday by signing an agreement with GlaxoSmithKline (China) R&D Co. Ltd. to advance Signum's phosphatase screening technology, which targets the phosphoprotein phosphatase 2A (PP2A) as a key mechanism in Alzheimer's disease (AD). Read More
WASHINGTON – The SEC is taking a get-tough stance on reverse mergers, approving stricter listing standards for the three major U.S. listing markets. Read More
For Avaxia Biologics Inc., of Lexington, Mass., its $2.2 million Series A financing round might be called heaven-sent. It's led by angels, rather than typical venture capitalist investors. Read More
• Adolor Corp., of Exton, Pa., reported third quarter sales of $7.8 million for post-bowel surgery drug Entereg (alvimopan), a 20 percent increase over the third quarter last year, but a quarter-over-quarter decrease. Read More
• Cytos Biotechnology Ltd., of Zurich, Switzerland, convened a bondholders' meeting on Nov. 10 to approve a proposed restructuring of outstanding convertible bonds, but failed to get sufficient votes to pass the proposal. Cytos said it will try to obtain further votes from bondholders who did not cast their votes. Read More
• BioDelivery Sciences International Inc., of Raleigh, N.C., said it started a confirmatory study of a formulation of buprenorphine and naloxone using BDSI's BioErodible MucoAdhesive drug delivery technology. The study will be used to select the final doses of BEMA Buprenorphine/Nalaxone to be used in the pivotal bioequivalence study compared to Suboxone set to start in January 2012. Read More
